Ascletis Pharma Inc. Reports Positive 28-Day ASC50 POC Data
Ascletis reported a 48.9% placebo-adjusted PASI reduction after 28 days of once-daily 200 mg ASC50 in mild-to-moderate plaque psoriasis, with a 6.5-day half-life and mild AEs. PASI reduction reached 65.9% 15 days after the last dose.Material DetailsContext by AI AnalystEarly clinical proof-of-conce…